Clicky

CSL Limited  (CSL)

Description: CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.


Keywords: Biotechnology Pharmaceutical Biopharmaceutical Pharmaceutical Products Pharmacology Diagnostic Products Therapeutic Products Intellectual Property In Vitro In Vitro Diagnostic Products Plasma Products Csl Behring Csl Limited Behring Non Plasma Biotherapeutic Products

Home Page: www.csl.com.au

CSL Technical Analysis

45 Poplar Road
Parkville, VIC 3052
Australia
Phone: 61 3 9389 1911


Officers

Name Title
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer
Dr. Paul F. McKenzie Ph.D. Chief Operating Officer
Mr. Mark Dehring Head of Investor Relations
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel
Christina Hickie Sr. Mang. of Communications
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production
Ms. Jemimah Brennan Head of Communications - Asia Pacific

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 43.1034
Trailing PE: 39.48
Price-to-Book MRQ: 6.7258
Price-to-Sales TTM: 13.317
IPO Date:
Fiscal Year End: June
Full Time Employees: 30000
Back to stocks